Free Stock & ETF Comparisons

Compare AstraZeneca's broad oncology and respiratory pipeline against Gilead's near-monopoly HIV treatment franchise and expanding cancer drug portfolio.

Compare AbbVie's Skyrizi/Rinvoq-led recovery from Humira's patent cliff against AstraZeneca's oncology pipeline depth and international sales mix.

Compare UnitedHealth's diversified insurance and Optum services business against Humana's concentrated Medicare Advantage exposure and its sensitivity to reimbursement rate changes.

Compare UnitedHealth's scale across commercial, Medicare, and Optum services against Centene's concentrated Medicaid managed care business and its margin pressures.

Compare UnitedHealth's massive scale and diversification against Oscar Health's smaller, tech-forward individual ACA marketplace insurance model and its path to consistent profitability.

Compare Abbott's diversified medical device, diagnostics, and nutrition portfolio against Stryker's more focused orthopedic implants, surgical robotics (Mako), and hospital equipment business.

Compare Elevance Health's Medicaid/Medicare Advantage mix against Cigna's PBM-heavy model on medical loss ratio and growth.

Compare Elevance Health and UnitedHealth Group by membership growth, Optum-style diversification, and valuation discount.

Compare Elevance Health's pure managed-care model against CVS Health's pharmacy-plus-insurance (Aetna) integration.

Compare DexCom's continuous glucose monitoring pure-play against Medtronic's diversified device portfolio on growth and margins.

Compare Stryker's orthopedics and surgical-equipment franchise against Boston Scientific's cardiovascular and endoscopy portfolio.

Compare Stryker's broad orthopedics/MedSurg portfolio against Intuitive Surgical's da Vinci robotic-surgery platform economics.

Compare Boston Scientific's cardiovascular device pipeline against Abbott's diversified devices, diagnostics, and nutrition business.

Compare Cigna's PBM-integrated commercial insurance model against Molina Healthcare's government-program-focused book.

Compare Stryker's orthopedics-led growth against Medtronic's broader, slower-growing diversified device portfolio.

Compare Veeva's life-sciences-focused cloud platform against Veradigm's smaller EHR-and-data healthcare IT business.

Compare Insulet's Omnipod tubeless-pump growth and margin scale against Tandem Diabetes Care's smaller, more competitive pump platform.

Compare Dentsply Sirona's dental-equipment-and-consumables turnaround against Align Technology's Invisalign clear-aligner growth franchise.

Compare Chewy's online pet-supply-and-pharmacy subscription growth against IDEXX's veterinary-diagnostics recurring-revenue instrument base.

Compare Mettler-Toledo's precision weighing-and-analytical-instrument margins against Agilent's broader life-sciences-and-diagnostics instrument portfolio.

Compare Medtronic's broader diabetes-and-cardiac-device portfolio against Boston Scientific's faster-growing structural-heart and electrophysiology business.

Compare Edwards Lifesciences' heart-valve-replacement pure-play focus against Boston Scientific's broader structural-heart-and-cardiac-rhythm portfolio.

Compare Moderna's broader mRNA-pipeline diversification beyond COVID vaccines against BioNTech's oncology-focused pipeline and Pfizer partnership.

Compare Bristol-Myers Squibb's newer-drug-launch pipeline against Pfizer's diversified but slower-growing post-pandemic portfolio.

Compare Exelixis' Cabometyx-concentrated oncology-royalty model against Incyte's broader hematology-oncology-and-dermatology pipeline.

Compare Novo Nordisk's commercialized obesity and diabetes franchise against Viking Therapeutics' pre-revenue clinical pipeline.

Compare Viking's binary clinical outcomes against Hims & Hers' consumer telehealth subscription model built on top of existing therapies.

Compare Hims & Hers' direct-to-consumer growth and platform risk against Amgen's diversified biologics portfolio and dividend.

Compare Novo Nordisk's GLP-1-driven growth and concentration risk against Amgen's broader portfolio and income profile.

Compare Medtronic's breadth across cardiac, diabetes, and surgical against Zimmer Biomet's concentrated hip and knee franchise.

Compare Boston Scientific's electrophysiology-led growth across many franchises against Insulet's single-product Omnipod concentration.

Compare Edwards' structural heart concentration and competitive risk against Abbott's devices, diagnostics, and nutrition breadth.